We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)199.70+5.47 (+2.82%)as of 4 Nov 2026
Funds that hold it7One fund per scheme
Held through a master fund70 buy the stock themselves
Largest weight in a single fund5.42%Of that fund's NAV
Median weight2.61%Half the funds hold more than this
What does RVMD do
Revolution Medicines, Inc.
Develops cancer drugs targeting RAS genes, which drive many types of cancer. The company is still in clinical trials and has no drug sales revenue yet
RAS inhibitors in clinical trialsPancreatic and lung cancer research programmes
Which funds let you invest in RVMD
Sorted by weight held, largest first
Investors in Thailand can buy RVMD through 7 mutual funds open to retail investors. Most of them (7 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds RVMD.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
ONEAM
How Thai money reaches RVMD
6 master funds
Master fund
Thai funds using this route
Master fund's RVMD weight
Baillie Gifford Worldwide Discovery Fund
2
2.61%
Tema Oncology ETF
1
5.42%
several master funds (JHHBIU2 LX, ARKG US)
1
4.36%
Janus Henderson Horizon Biotechnology Fund
1
4.28%
several master funds
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Showing 7 of 7 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Valuation and key ratios
Revolution Medicines, Inc. · NASDAQ · Fiscal year ends in January
Market cap42.7B USD0.21 billion shares
P/EN/AFY2025 EPS is negative
Forward P/EN/ABased on forecast 12-month earnings
P/SN/A
EV/EBITDAN/A
Dividend yield0.00%0.00 USD per share a year
ROE−58.1%Net profit ÷ shareholders' equity
Debt to equity (D/E)0.00xInterest-bearing debt
BetaN/AAgainst the S&P 500
Gross marginN/AFY2025
Operating margin0.0%FY2025
Net margin0.0%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S, EV/EBITDA and Beta aren't available for this company yet
Company health made simple
From the FY2025 statements
Sales growthN/A
Yearly average over the last 4 years · Latest annual sales 0.0M USD
Profit from sales0%Thin margin
For every 100 dollars of sales, about 0 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+241.0%Up
Now 9.7% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows N/A a year on average · EPS grows N/A a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY202129.0M USD−187.0M USD
FY202235.0M USD−249.0M USD
FY202312.0M USD−436.0M USD
FY20240.0M USD−600.0M USD
FY20250.0M USD−1.1B USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q4 FY20231.0M USD−162.0M USD
Q1 FY20240.0M USD−116.0M USD
Q2 FY20240.0M USD−133.0M USD
Q3 FY20240.0M USD−156.0M USD
Q4 FY20240.0M USD−195.0M USD
Total revenue
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
29.0M USD
35.0M USD
12.0M USD
0.0M USD
0.0M USD
Operating profit
−188.0M USD
−258.0M USD
−487.0M USD
−690.0M USD
−1.2B USD
Net profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 199.70 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.50 on a scale of −1 to +1 · 1253 bars
RSI(14)
56.4
ADX(14)
17.0
Position in the price range
50%
Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 261 bars
RSI(14)
60.8
ADX(14)
43.4
Position in the price range
87%
Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars
RSI(14)
83.0
ADX(14)
54.7
Position in the price range
89%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
189.72
191.78
Above
20 days
189.56
192.05
Above
50 days
198.21
193.86
Above
100 days
193.81
185.77
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
56.41
Up
MACD(12,26)
−1.21
Down
ADX(14)
17.03
Neutral
ATR(14) % of price
2.04
Neutral
Support and resistance (weekly pivots)
s3179
s2181
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in RVMD, not the look-through weight · Past performance is not a guarantee of future performance
LHLONGEVITYLH LONGEVITY HEALTHCARE FUND
ASP-IHEALTH
DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND
ONE-DISC-ASSFONE DISCOVERY FUND
BCAP-XHEALTHBCAP NEXT GEN Health Fund
KT-USSM-AKTAM US Small Cap Equity Passive Fund